Skip to main content
VIVS
NASDAQ Life Sciences

VivoSim Regains Nasdaq Compliance, Projects 500%+ Revenue Growth, and Holds $10.1M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.376
Mkt Cap
$6.094M
52W Low
$0.314
52W High
$5.3
52W Position info
20% above low
Off High info
93% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

VIVS sits 20% above its 52-week low of $0.314 on light trading volume (0.3× avg).

Summary

VivoSim Labs announced it has regained Nasdaq compliance, holds $10.1M in cash, and expects 500%+ revenue growth in fiscal 2027, though outstanding shares have quadrupled due to warrant exercises.


Key Events · Earnings and Guidance · VIVS

  • Nasdaq Compliance Regained

    The Nasdaq Listing Qualifications Staff confirmed VivoSim now meets the $2.5M minimum stockholders' equity requirement, resolving the July 24 delisting notice.

  • Cash Position Bolstered to $10.1M

    Preliminary cash on hand as of August 3, 2026 was ~$10.1M, driven by a $5M Lilly milestone payment, $1M escrow release, and $4M financing (net ~$3.6M).

  • 500%+ Revenue Growth Guidance for FY2027

    Management reiterated guidance for over 500% revenue growth in fiscal 2027, citing progress in marketing NAM-based contract research services to pharma companies.

  • Significant Dilution from Warrant Exercises

    9.9M shares were issued upon warrant exercises between July 15-31, 2026, increasing outstanding shares from 3.2M to 13.4M — a 4x increase.


Analysis · VIVS · Life Sciences

VivoSim Labs has resolved its immediate Nasdaq delisting threat by regaining compliance with the $2.5M stockholders' equity requirement, a critical step after the July 24 delisting notice. The company now holds $10.1M in cash, largely from a $5M Lilly milestone and a $4M financing, which extends its runway despite the going concern warning. Management also guided for over 500% revenue growth in fiscal 2027, signaling a potential inflection in its NAM-based contract research services. However, the share count has quadrupled to 13.4M due to warrant exercises, meaning significant dilution has already occurred.

At the time of this filing, VIVS was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $0.31 to $5.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VIVS - Latest Insights

VIVS
Jul 24, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4189
Real-time Price: $0.389 info
Change: -$0.0299 (-7%) info
Market Cap: $6.094M info
VIVS
Jul 17, 2026, 8:53 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.5401
Real-time Price: $0.389 info
Change: -$0.1511 (-28%) info
Market Cap: $6.094M info
VIVS
Jul 17, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5487
Real-time Price: $0.389 info
Change: -$0.1597 (-29%) info
Market Cap: $6.094M info
VIVS
Jul 16, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $0.7602
Real-time Price: $0.389 info
Change: -$0.3712 (-49%) info
Market Cap: $6.094M info
VIVS
Jul 15, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.66
Real-time Price: $0.389 info
Change: -$2.27 (-85%) info
Market Cap: $6.094M info